Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 18 Brain Neoplasms 9 Glioblastoma 5 Glioma 4 Neoplasms 3 Uterine Cervical Neoplasms 2 Urogenital Diseases 2 Disease 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostate Adenocarcinoma 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, Follicular 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Lobular 1 Breast Neoplasms 1

Interventions

Trastuzumab 597 Paclitaxel 562 Cyclophosphamide 545 Docetaxel 479 Capecitabine 387 Letrozole 350 Fulvestrant 311 Doxorubicin 285 Carboplatin 277 Tamoxifen 257 Anastrozole 219 exemestane 211 Epirubicin 210 Radiotherapy 197 Bevacizumab 189 pertuzumab 177 Gemcitabine 163 Vinorelbine 162 pembrolizumab 161 Lapatinib 161 palbociclib 152 Exercise 132 Fluorouracil 118 Albumin-Bound Paclitaxel 116 eribulin 108 Magnetic Resonance Spectroscopy 108 130-nm albumin-bound paclitaxel 107 Everolimus 103 Taxes 96 Cisplatin 92

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × fluciclovine F-18 × Clear all

NCT03036943 2018-12-19

FRONTIER

University of Oxford

Phase NA Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡